← All trials
NCT06459180
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 24, 2024
- Primary completion
- Oct 23, 2028
- Completion date
- Oct 23, 2028
- First posted
- Jun 14, 2024
- Last posted
- Nov 11, 2024
- Enrollment
- 686
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- MerckLead sponsor
- GOG Foundation, Inc.Collaborator
- European Network for Gynaecological Oncological TrialCollaborator
- MerckOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.